US · Healthcare · Biotechnology
EPS came in at -0.90 against a street estimate of -1.27 — a beat of 29.1%.
Analysts rate Ultragenyx a strong buy (19 buy, 1 hold, 0 sell out of 20) with an average price target of $27.00.
CONFIDENT Q2 revenue hit $214M (record quarterly, +28.5% YoY). Three major catalysts ahead: DTX401 (GSDIa) PDUFA Aug 23, UX111 (Sanfilippo) PDUFA Sept 19, GTX-102 Phase III readout Sept/Oct. Path to 2027 profitability on track. Q2 2026 Global infrastructure enables 75% overlap between new gene therapy centers and existing Dojolvi/Mepsevii sites. 5th and 6th product launches leverage established field presence. Analysts pressed Angelman endpoint design (MDRI power, placebo risk, centralized raters, discontinuation rates), setrusumab regulatory path (BMD acceptance, additional data needed), and launch profitability sensitivity. Management emphasized FDA alignment on endpoints, consistent safety, multiple profitability levers beyond gene therapy contribution. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.40% |
| Vanguard Portfolio Management, LLC | 5.46% |
| State Street Corp | 5.09% |
| AQR Capital Management LLC | 4.64% |
| Vanguard Capital Management, LLC | 4.25% |
| RTW INVESTMENTS, LLC | 3.70% |
| Sands Capital Management, LLC | 3.20% |
| Sofinnova Ventures | 3.19% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • Report Date: September 2, 2026 • Company: Ultragenyx Pharmaceutical Inc. (Nasdaq: RA | 2026-09-02 |
| Company announcement · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • FDA granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr/DTX4 | 2026-08-19 |
| Company announcement · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. – 8-K SUMMARY Filing Date: August 11, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Patent Settlement on DOJOLVI: Ultrage | 2026-08-11 |
| Quarterly report · Q2 2026 ULTRAGENYX PHARMACEUTICAL INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Product Sales (6 months): $201 million vs. $172 million (2025) — up 17% • | 2026-08-05 |
| Results announced · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $214 million (highest quarterly revenue in comp | 2026-08-04 |
| Quarterly report · Q1 2026 ULTRAGENYX PHARMACEUTICAL INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues (Q1 2026): $136 million (product sales $89M + royalty revenu | 2026-05-06 |
| Proxy statement · Q2 2026 ULTRAGENYX PHARMACEUTICAL INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of three Class I directors | 2026-03-27 |
| Annual report FY2025 ULTRAGENYX PHARMACEUTICAL INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: $3.4 billion as of June 30, 2025 • Shar | 2026-02-18 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ultragenyx — free to start.
Google PlayApp StoreData updated 2026-09-18.